Recursion Pharmaceuticals, Inc. (RXRX)
4.78
+0.66
(+16.02%)
USD |
NASDAQ |
Oct 05, 16:00
4.78
0.00 (0.00%)
After-Hours: 06:41
Recursion Pharmaceuticals Cash from Operations (Quarterly) : -105.95M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -105.95M |
| March 31, 2026 | -81.10M |
| December 31, 2025 | -46.07M |
| September 30, 2025 | -117.36M |
| June 30, 2025 | -76.42M |
| March 31, 2025 | -131.96M |
| December 31, 2024 | -115.43M |
| September 30, 2024 | -59.22M |
| June 30, 2024 | -82.22M |
| March 31, 2024 | -102.30M |
| December 31, 2023 | -74.08M |
| September 30, 2023 | -72.92M |
| June 30, 2023 | -67.47M |
| Date | Value |
|---|---|
| March 31, 2023 | -73.32M |
| December 31, 2022 | -44.75M |
| September 30, 2022 | -54.54M |
| June 30, 2022 | -61.62M |
| March 31, 2022 | 77.39M |
| December 31, 2021 | -61.16M |
| September 30, 2021 | -33.05M |
| June 30, 2021 | -33.65M |
| March 31, 2021 | -30.76M |
| December 31, 2020 | 8.573M |
| September 30, 2020 | -19.46M |
| June 30, 2020 | -16.70M |
| March 31, 2020 | -17.82M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Editas Medicine, Inc. | -29.57M |
| Amgen, Inc. | 4.002B |
| Halozyme Therapeutics, Inc. | 240.89M |
| Novavax, Inc. | -72.81M |
| AVITA Medical, Inc. | -3.630M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -1.959M |
| Cash from Financing (Quarterly) | -1.267M |
| Free Cash Flow | -354.26M |
| Free Cash Flow Per Share (Quarterly) | -0.2027 |
| Free Cash Flow to Equity (Quarterly) | -102.17M |
| Free Cash Flow to Firm (Quarterly) | -107.60M |
| Free Cash Flow Yield | -14.56% |